MarketLens
Sign Up
Stock AnalysisPro

What Does the Second FDA Rejection Mean for Replimune's RP1

6 months ago
SHARE THIS ON:

What Does the Second FDA Rejection Mean for Replimune's RP1

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

Already a Pro member? Log in
SHARE THIS ON:

Related Articles

What Does Ultragenyx's Latest FDA Clearance Mean for Investors

What Does Ultragenyx's Latest FDA Clearance Mean for Investors

7 months ago
What Does FDA Clearance Mean for AI-Powered Diagnostics

What Does FDA Clearance Mean for AI-Powered Diagnostics

5 months ago
What Does the FDA Warning Mean for Medline's Operations

What Does the FDA Warning Mean for Medline's Operations

6 months ago
What Does Teva's Recent FDA Acceptance Mean for Investors

What Does Teva's Recent FDA Acceptance Mean for Investors

8 months ago

Category

TopFeaturedPro OnlyStock AnalysisInvestment IdeasETFsCrypto

You may also like

Stock News•2 months ago

Stockholder Alert: Robbins LLP Informs Investors of the Replimune Group, Inc. Class Action

Replimune Group faces a securities class action investigation after Robbins LLP alleged the company misled investors about the efficacy and viability of its lead candidate, RP1. The probe could pressu...
REPL
Stock News•2 months ago

Replimune Announces Favorable Outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced Melanoma

Replimune's RP1 combo therapy for advanced melanoma received a favorable FDA advisory committee vote, a key step toward potential BLA approval for patients who progressed on anti-PD-1 therapy.
REPL
Stock News•3 months ago

Replimune Lead Drug Trial Data Deemed 'Not Interpretable' by FDA Staff

Replimune (REPL) stock fell after FDA staff deemed RP1 trial data 'not interpretable' ahead of an advisory committee meeting for the skin cancer therapy.
REPL

Breaking News

View All →
Earnings
Earnings Surprise
Regional Banks
Analyst Consensus
Corporate Earnings
Debt/Share Issuance
EPS Beat/Miss

Featured Articles

DoorDash (DASH): Founder Selling Signals Liquidity, Not Lack of Confidence Amid Robust Growth

DoorDash (DASH): Founder Selling Signals Liquidity, Not Lack of Confidence Amid Robust Growth

2 months ago
Sea Limited's Growth Momentum Outweighs COO's Programmed De-risking

Sea Limited's Growth Momentum Outweighs COO's Programmed De-risking

2 months ago
Arista Networks' AI Momentum Encounters Founder's Planned Profit-Taking

Arista Networks' AI Momentum Encounters Founder's Planned Profit-Taking

2 months ago

Top Headlines

View More →
Stock News•20 minutes ago

GOOGL, GOOG Investors Have Opportunity to Lead Alphabet Inc. Securities Fraud Lawsuit

Stock News•1 hour ago

CrowdStrike Holdings (CRWD) Laps the Stock Market: Here's Why

Stock News•1 hour ago

Nvidia (NVDA) Surpasses Market Returns: Some Facts Worth Knowing

Stock News•1 hour ago

Apple (AAPL) Stock Falls Amid Market Uptick: What Investors Need to Know

Stock News•1 hour ago

Palo Alto Networks (PANW) Laps the Stock Market: Here's Why